191 related articles for article (PubMed ID: 11197224)
1. Transient factor VIII inhibitor in a hemophilia patient after staphylococcal septic shock syndrome.
Yamamoto K; Niiya K; Shigematu T; Kiguchi T; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Shima M; Harada M
Int J Hematol; 2000 Dec; 72(4):517-9. PubMed ID: 11197224
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
3. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
4. Rapid decrease in high titer of factor VIII inhibitors upon immunosuppressive treatment in severe postpartum acquired hemophilia A.
Pejsa V; Grgurević I; Kusec R; Gaćina P
Croat Med J; 2004 Apr; 45(2):213-6. PubMed ID: 15103761
[TBL] [Abstract][Full Text] [Related]
5. [Immunosuppressive treatment of a spontaneous inhibitor hemophilia A using cyclophosphamide, vincristine and prednisone following prior Factor VIII stimulation].
Dürig J; de Wit M; Fiedler W; Marx G; Hossfeld DK
Schweiz Med Wochenschr; 1996 Nov; 126(47):2026-31. PubMed ID: 8984611
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
[TBL] [Abstract][Full Text] [Related]
7. [Macrohaematuria post-partum: an unusual case of acquired haemophilia after pregnancy].
Prencipe MA; D'Errico M; Di Giorgio G; Gatta G; Gesuete A; Nobile M; Stallone C
G Ital Nefrol; 2002; 19(2):204-8. PubMed ID: 12195420
[TBL] [Abstract][Full Text] [Related]
8. Surgery for a chronic cystic hematoma on the right thigh in a hemophiliac A with a potent factor VIII inhibitor.
Masuhara K; Shimizu T; Kawasaki N; Fukui H; Sakai Y; Shima M; Mikami S; Yoshioka A
Nihon Seikeigeka Gakkai Zasshi; 1982 Dec; 56(12):1719-27. PubMed ID: 6820658
[TBL] [Abstract][Full Text] [Related]
9. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
Sultan Y; White GC; Aronstam A; Bosser C; Brackmann HH; Brochier G; Gormsen J; Mariani G; Roberts HR; Scarabin Y
Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516
[TBL] [Abstract][Full Text] [Related]
10. [Long-term response to rituximab in a patient with acquired hemophilia].
García-Chávez J; Vela-Ojeda J; García-Manzano A; Majluf-Cruz A
Rev Invest Clin; 2011; 63(2):210-2. PubMed ID: 21717725
[TBL] [Abstract][Full Text] [Related]
11. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
Singleton E; Smith J; Kavanagh M; Nolan B; White B
Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
[TBL] [Abstract][Full Text] [Related]
12. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
Mariani G; Kroner B;
Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
[TBL] [Abstract][Full Text] [Related]
13. Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies.
Leggett PL; Doyle D; Smith WB; Culpepper W; Cooper S; Ochsner JL
J Thorac Cardiovasc Surg; 1984 Apr; 87(4):556-60. PubMed ID: 6423912
[TBL] [Abstract][Full Text] [Related]
14. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
16. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
17. Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
Landolfi R; de Cristofaro R; Lazzareschi I; Riccardi R; Mariani G
Haematologica; 2000 Oct; 85(10 Suppl):73-4. PubMed ID: 11187877
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to factor VIII in hemophilia A patients.
Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
Peerlinck K; Hermans C
Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
[TBL] [Abstract][Full Text] [Related]
20. [Acquired hemophilia A developed at relapse of minimal change nephrotic syndrome].
Shimizu H; Saitoh T; Osaki Y; Yamane A; Gohda F; Irisawa H; Yokohama A; Uchiumi H; Handa H; Matsushima T; Tsukamoto N; Karasawa M; Murakami H; Nojima Y
Rinsho Ketsueki; 2007 Jun; 48(6):514-7. PubMed ID: 17633102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
